ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has imposed a ban on the sale of several batches of substandard medicines, including two cough syrups, following laboratory tests that found them to be hazardous to public health.
DRAP’s investigation revealed that eight batches of two cough syrup brands, Tussin DM Suspension and one batch of Arp Powder, were substandard.
Additionally, four batches of other medicines, including Metrovan Syrup, Ann-vil Injection, and seven batches of Torax and Zond Syrup, were also identified as substandard.
Laboratory tests indicated that Torax and Zond Syrups contained ethylene glycol levels exceeding safe limits, posing significant health risks to consumers.
In response, DRAP immediately issued a recall alert for these hazardous drugs and implemented a ban on the sale of the affected batches to safeguard public health.
This decision follows the Punjab Drug Control Directorate’s submission of initial samples of the suspect medicines to DRAP, prompting a comprehensive investigation and regulatory action.
DRAP has emphasized the importance of consumer safety and urged the public to remain vigilant when purchasing medicines.
The authority has assured the public that it will continue to monitor the pharmaceutical market closely and take swift action against any substandard or adulterated drugs to protect the health and well-being of the people of Pakistan.
